Skip to main content

Bringing proven ECP therapy to more patients – efficiently, affordably, at scale

Wave PROTM is a scalable cardiovascular therapy designed for safety, simplicity, and measurable patient benefit. Its portable, reimbursable, and clinically validated design integrates seamlessly into outpatient service lines, supported by a low-cost lease model that minimizes capital expenditure.

Wave PROTM adds measurable cardiac benefit without major infrastructure or staffing increases

A Revenue-Positive Therapy Enabling Expanded CSA Treatment

As healthcare systems seek to expand non-invasive cardiac options without complex overhead, the Wave PROTM offers a practical solution.

Its small footprint (24”x24”), portable form factor (just 34 kg) and automated therapy delivery make it ideal for outpatient centers, rehab programs, and community health settings. Each unit delivers proven hemodynamic outcomes 1 and rapid ROI potential.

Value to the Institution

Wave PROTM expands non-invasive ECP therapy options by offering  an automated, software-guided therapy designed for scalable, resource-efficient delivery, requiring minimal maintenance and backed by a full warranty.

Overview

  • Non-surgical therapy option for patients with drug-refractory CSA and no revascularization options1
  • More capital-efficient, space efficient and staff efficient alternative compared to legacy ECP systems
  • Expands service offerings without additional infrastructure
  • One-hour treatment sessions with minimal staffing requirements1
  • Durable, reusable sleeves with minimal upkeep as part of a complete turnkey system with full warranty and dedicated support for uninterrupted operation
  • Reimbursable under HCPCS code5, ensuring straightforward integration into clinical billing and reimbursement workflows

  • Calf only pulse synchronized compression delivering diastolic augmentation and systolic unloading1

  • Streamlined setup designed to minimize preparation time and staff burden

  • WaveCRESST study demonstrated equivalent hemodynamic benefit and improved patient comfort1

  • FDA-cleared based on the WaveCRESST clinical trial1

  • Built under a comprehensive quality and risk-management program

  • Rigorously tested to industry standards

  • Adds reimbursable therapy for Chronic Stabile Angina (CSA) 5
  • Diversifies cardiovascular and wellness service lines
  • Portable system allows flexible deployment
  • Turnkey solution featuring full warranty on all components with hassle-free replacement of all elements including worn-out sleeves
  • Low start up cost through a monthly lease model that eliminates major capital expenditure and minimizes ongoing operating costs
  • Small footprint (24”x24”), portable form factor (just 34 kg). Plug-and-play setup with existing compressed air infrastructure
  • Efficient personnel usage: short training duration and automated therapy delivery (PPG sensor and intelligent timing algorithm) after setup with the patient
  • Engineered for a quieter experience than conventional ECP therapy with low-maintenance operation
  • 60-minute sessions enable efficient scheduling

Onsite Implementation

Pression provides onboarding, staff training, marketing collateral for referring physicians and reimbursement education to streamline adoption and ensure measurable ROI.

Clinical Confidence

The Wave PROTM is clinically proven in the United States to offer equivalent diastolic augmentation1 and is compliant with applicable national and international standards and regulatory guidelines.

Empower your institution with expanded options for cardiac therapy

Contact Clinical Adoption Team

Footnotes:
[1] National Library of Medicine (U.S.). WAVECRESST Clinical Trial Results. ClinicalTrials.gov identifier: NCT06571370. Updated September 3, 2024. Accessed January 28, 2026. https://clinicaltrials.gov/study/NCT06571370
[2] Shah SA, Shapiro RJ, Mehta R, Snyder JA. Impact of enhanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis. Pharmacotherapy. 2010 Jul;30(7):639-45. https://doi.org/10.1592/phco.30.7.639.
[3] Pettersson, T., Bondesson, S., Cojocaru, D. et al. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord 6, 28 (2006). https://doi.org/10.1186/1471-2261-6-28
[4] Wu, Eline MNSc, RN; Desta, Liyew PhD, MD; Broström, Anders PhD, RN; Mårtensson, Jan PhD, RN. Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. The Journal of Cardiovascular Nursing 35(4):p 375-385, 7/8 2020. | https://doi.org/10.1097/JCN.0000000000000638
[5] Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. CMS Publication 100-04. Updated periodically. https://www.cms.gov/regulations-and-guidance/guidance/manuals/internet-only-manuals-ioms-items/cms018903
[6] Zuj KA, Prince CN, Hughson RL, Peterson SD. Enhanced muscle blood flow with intermittent pneumatic compression of the lower leg during plantar flexion exercise and recovery. J Appl Physiol (1985). 2018 Feb 1;124(2):302-311. https://doi.org/10.1152/japplphysiol.00784.2017. 

IMPORTANT SAFETY INFORMATION 
Please see the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions. 

Indications for Use 
The Pression Wave PRO External Counter-Pulsation System is indicated for the treatment of chronic stable angina (CSA) that is refractory to optimal anti-anginal medical therapy and without options for revascularization in adult patients that weigh greater than 40kg. In addition, it is intended for use in healthy adult patients to provide improvement in vasodilation, increased VO2, and increased blood flow. It is intended for use under the supervision of a healthcare professional.
Contraindications 
The Pression Wave PRO is contraindicated in patients with: moderate to severe peripheral vascular disease (PVD), cardiac catheterization or arterial femoral puncture in the past 2 weeks, pacemaker or other implantable pulse generating device, valve disease, including aortic insufficiency, abdominal or thoracic aortic dissection or aortic/cerebral aneurysms requiring clinical intervention, severe pulmonary disease, bleeding diathesis, coagulopathy, pregnancy, baseline heart rate <40 BPM or >120 BPM, arrhythmia and/or abnormal heart rhythm; major hand injuries or amputation of both hands, local infection on one or both calves, severe lower extremity vaso-occlusive disease, open or freshly healed ulcers or other wounds or otherwise fragile skin from the knee to the ankles, active thrombophlebitis, uncontrolled hypertension (greater than 180/110 mmHg), stents (arterial/venous) or medical implants in the calves, unhealed wounds/fractures below the waist or lower limb amputation, any major surgery within the past 3 months (defined as highly invasive procedures requiring the removal of, or trauma to, organ tissue, an organ, or body part that requires general anesthesia and/or results in an extended hospital stay).
Warnings & Precautions
The Pression Wave PRO must be used under the supervision of a qualified healthcare professional. The PPG sensor is not intended to be used under motion or low perfusion conditions. Cotton stockinettes must be worn under the calf sleeves to prevent skin irritation and/or discomfort. The patient’s fingers should be clean and devoid of nail polish/extensions to avoid compromise of the PPG signal. Use of accessories and cable equipment other than those provided or specified by Pression could result in increased electromagnetic emissions or decreased electromagnetic immunity and can result in improper operation. Refer to the IFU (LBL016) for additional warnings and precautions.
Potential Adverse Events
Potential adverse events associated with the Wave PRO System are the same as for any ECP system, including paresthesia, edema/swelling, skin abrasions, bruises, blisters and leg/back pain.
Caution 
Federal (USA) law restricts this device to sale by or on the order of a physician.